DrugPatentWatch Database Preview
Patent: 8,642,737
» See Plans and Pricing
Summary for Patent: 8,642,737
| Title: | Nucleophilic catalysts for oxime linkage |
| Abstract: | The invention relates to materials and methods of conjugating a water soluble polymer to an oxidized carbohydrate moiety of a therapeutic protein comprising contacting the oxidized carbohydrate moiety with an activated water soluble polymer under conditions that allow conjugation. More specifically, the present invention relates to the aforementioned materials and methods wherein the water soluble polymer contains an active aminooxy group and wherein an oxime or hydrazone linkage is formed between the oxidized carbohydrate moiety and the active aminooxy group on the water soluble polymer, and wherein the conjugation is carried out in the presence of a nucleophilic catalyst. |
| Inventor(s): | Siekmann; Juergen (Vienna, AT), Haider; Stefan (Prinzersdorf, AT), Rottensteiner; Hanspeter (Vienna, AT), Ivens; Andreas (Zurich, CH), Turecek; Peter (Klosterneuburg, AT), Zoechling; Oliver (Vienna, AT) |
| Assignee: | Baxter International Inc. (Deerfield, IL) Baxter Healthcare SA (Glattpark (Opfikon), CH) |
| Application Number: | 13/194,038 |
| Patent Claims: | see list of patent claims |
Details for Patent 8,642,737
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amgen | XGEVA | denosumab | INJECTABLE; SUBCUTANEOUS | 125320 | 002 | 2010-06-01 | Start Trial | Baxter International Inc. (Deerfield, IL) Baxter Healthcare SA (Glattpark (Opfikon), CH) | 2039-02-26 | RX | Orphan | search |
| Amgen | PROLIA | denosumab | INJECTABLE; SUBCUTANEOUS | 125320 | 001 | 2010-06-01 | Start Trial | Baxter International Inc. (Deerfield, IL) Baxter Healthcare SA (Glattpark (Opfikon), CH) | 2039-02-26 | RX | Orphan | search |
| Abbvie Inc | HUMIRA | adalimumab | VIAL | 125057 | 002 | 2002-12-31 | Start Trial | Baxter International Inc. (Deerfield, IL) Baxter Healthcare SA (Glattpark (Opfikon), CH) | 2039-02-26 | RX | Orphan | search |
| Abbvie Inc | HUMIRA | adalimumab | SYRINGE | 125057 | 001 | 2002-12-31 | Start Trial | Baxter International Inc. (Deerfield, IL) Baxter Healthcare SA (Glattpark (Opfikon), CH) | 2039-02-26 | RX | Orphan | search |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patent Family for US Patent 8,642,737
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2011012850 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2011017055 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2012016131 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2012087838 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
